EGFR and pancreatic adenocarcinoma: In 2008, Patra et al. were the first to design an antibody-conjugated AuNP to target the overexpression of epidermal growth factor receptor (EGFR) in pancreatic adenocarcinoma, using cetuximab to deliver the anticancer drug gemcitabine [35].